(833) 317-6278
Book a Demo
Hamza Tariq
Gray shield icon
Is this you?
Claim your profile.

Hamza Tariq

Crypto Editor/Writer

AS SEEN ON
Coinspeaker, ReadWrite, techlapse

Geo Focus

United States (National)

Coverage Attributes:

Beta
Investment Analysis: 23 %
Cites Data: 20 %
Review: 11 %
Press Release: 11 %
Industry Specific: 8 %

Themes Covered:

Not enough data icon

Not enough data

Most Recent Topics:

  • Crypto Exchanges
  • Crypto Regulation
  • Cryptocurrency
  • Cyber attacks
  • Data Breaches
  • Data Leaks
  • Phishing

Pitching Insights

Hamza Tariq's coverage demonstrates a strong focus on technology, privacy, and cybersecurity. His articles encompass reviews of tech products, industry-specific news related to data breaches and cyberattacks. Given this emphasis, individuals or companies with expertise in internet privacy, VPNs, online security practices and technologies would find Hamza Tariq's platform suitable for pitching relevant insights.

As his articles often include specific incidents of data breaches and cyber attacks affecting various entities worldwide (including government agencies), experts who can provide detailed analysis or commentary on these occurrences are likely to be well received by him. It is important to note that the geographic focus of the topics covered is global rather than restricted to any particular region.

This information evolves through artificial intelligence and human feedback. Improve this profile .

Journalists With Similar Coverage:

Based on similarity of content.
Alicia Hope

Alicia Hope

Publications
CPO Magazine
Most recent topics
Not enough data
Scott Ikeda

Scott Ikeda

Publications
CPO Magazine
Most recent topics
Not enough data
Eduard Kovacs

Eduard Kovacs

Contributing Editor
*********51@*******om
Publications
SecurityWeek
Most recent topics
Not enough data
Claudia Glover

Claudia Glover

Journalist
***********ver@**********com
Publications
Tech Monitor
Most recent topics
Not enough data
Daniel Croft

Daniel Croft

Journalist
**********ft@****************m.au
Publications
cyberdaily.au, Super Review, Lawyers Weekly, InvestorDaily
Most recent topics
Not enough data
Penka Hristovska

Penka Hristovska

Editor
Publications
Best Internet Security, Zephyrnet NFT
Most recent topics
Not enough data

Articles

GovInfoSecurity.com

Content by Hamza Tariq, Senior Solutions Engineer, CyberArk

By: Hamza Tariq

Hamza Tariq is a seasoned CyberArk Senior Solutions Engineer with over 20 years of experience in Privileged Access Management (PAM), IAM, and cybersecurity. He specializes in Cloud Security, Just-in-Time Access, Securing Remote Access, and Endpoint Privilege Management. He has helped clients across various industries protect critical assets, mitigate insider threats, and implement tailored enterprise PAM solutions. Outside of work, Hamza enjoys 3D printing, DIY projects, aqua scaping, and coaching the WAA Boys basketball team in Woodbury, MN.

BMJ

Karyotypic clonal fraction predicts adverse outcome in TP53-mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study

Karyotypic clonal fraction predicts adverse outcome in TP53-mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study

By: Talha Badar, Danica Wiredja, Madhu Menon, Haipeng Shao, Geoffrey D. Wool, Anamarija Perry, Qianghua Zhou, Anthony Findley, Anisha Jacob, Claudia Haferlach, Sinthujaa Velmurugan, Girish Venkataraman, Amandeep Kaur, Hong Chang, Emily Symes, Anna Stengel, Alexandra Rojek, Sharmila Ghosh, Jingjing Zhang, Peng Wang, Hamza Tariq, Daniel A. Arber, Ami B. Patel, David Sallman, Jay L. Patel, Payal Sojitra, Esha Patil, Carrie Fitzpatrick, Zenggang Pan, Madhavi Pandiri, Robert C Bell

We investigated the prognostic impact of blast counts, TP53 allelic state determinants (number of hits, del(17p), variant allele frequency, complex karyotype),and a novel karyotypic clonal cell fraction (≤50% clonal cells vs >50% clonal cells (termed ‘CK50’)) in 495 individuals with TP53- mutated ( TP53MUT ) myeloid neoplasms. Outcome examined was 24-month survival (OS24). The cohort (median age 71) included 29% (144/495) myelodysplastic syndromes (MDS)/MDS-acute myeloid leukaemia (AML) (1%–19% blasts) and 71% (351/495) AML (≥20% blasts), with 18% (81/460) having low CK50. Overall, 83% received front-line hypomethylating agents. Higher blast counts (<20% vs ≥20%) were marginally associated with CK50 (p=0.08). In the OS24 analysis, blast count showed a marginal association with OS24 (HR 1.3 (95% CI 1.0 to 1.6); p=0.07), while CK50 predicted significantly inferior outcomes (HR=1.7 (95% CI 1.2 to 2.3); p=0.002). In a multivariable model including all TP53 allelic state determinants, only CK50 and complex karyotype remained relevant for predicting adverse outcomes.

© 2025 Intelligent Relations